Soleno Therapeutics (SLNO) Long-Term Investments (2024 - 2026)

Soleno Therapeutics (SLNO) has 3 years of Long-Term Investments data on file, last reported at $273.4 million in Q1 2026.

• On a quarterly basis, Long-Term Investments changed N/A year-over-year to $273.4 million in Q1 2026; TTM through Mar 2026 was $273.4 million, a N/A change from a year earlier, with the FY2025 full-year figure at $200.6 million, up 637.26% from the prior year.
• Long-Term Investments for Q1 2026 stood at $273.4 million, up from $200.6 million in the prior quarter.
• Over the last five years, Long-Term Investments for SLNO reached as high as $273.4 million in Q1 2026 and fell as low as $7.0 million in Q2 2025.
• Historically, Long-Term Investments has averaged $78.8 million across 3 years, with a median of $28.2 million in 2024.
• On a YoY basis, Long-Term Investments climbed as much as 637.26% in 2025 and fell as far as 75.43% in 2025.
• Year by year, Long-Term Investments stood at $27.2 million in 2024, then soared by 637.26% to $200.6 million in 2025, then surged by 36.27% to $273.4 million in 2026.
• Per Business Quant data, the three most recent Long-Term Investments figures were $273.4 million in Q1 2026, $200.6 million in Q4 2025, and $57.1 million in Q3 2025.